Replies to post #14012 on Moderna Inc (MRNA)

[jondoeuk]

Data on mRNA-4359: ''The objective response rate was 24% in evaluable patients who received mRNA-4359 intramuscularly every three weeks for up to nine doses. Adding in patients with stable disease resulted in a 60% disease control rate. The trial is yet to reach the median duration of response.'' https://www.fiercebiotech.com/biotech/moderna-posts-melanoma-data-behind-decision-say-i-do-ido